March 23, 2025 – Riyadh, Saudi Arabia – Middle East Pharmaceutical Industries (SASE:4016), operating as Avalon Pharma, reported a significant increase in profit and revenue for the full-year 2024, driven by strong sales growth and operational efficiency.
📈 Financial Highlights
- Net Profit: SAR 79.9 million, up 21.4% from SAR 65.8 million in FY 2023.
- Earnings per Share (EPS): SAR 3.99, compared to SAR 3.29 the previous year.
- Revenue: Reached SAR 394 million, marking a 16.4% increase from SAR 338.4 million a year ago.
🔥 Growth Driven by Expanding Market Reach
Avalon Pharma’s double-digit revenue and profit growth reflects the company’s strengthening market position in Saudi Arabia and the broader region. The higher EPS highlights the company’s improved profitability and efficiency.
💡 Outlook and Market Confidence
The strong financial performance reinforces Avalon Pharma’s growth trajectory, with rising demand for its pharmaceutical products driving both top-line and bottom-line expansion. The company’s solid earnings growth is expected to bolster investor confidence in the Saudi-listed firm.
Avalon Pharma’s robust FY 2024 results mark a year of remarkable growth and profitability, positioning the company for continued success.
